On Thursday, in the course of current trade, Shares of Eli Lilly and Company (NYSE:LLY), gained 0.41%, and is now trading at $83.52, hitting its highest level.
Eli Lilly and Company, declared that detailed results of two pivotal Phase III studies for ixekizumab were published by The Lancet. The UNCOVER-2 and UNCOVER-3 clinical studies of more than 2,500 patients found ixekizumab to be statistically superior to etanercept and placebo on all measures of skin clearance. Patients treated with ixekizumab also demonstrated noteworthy and meaningful improvements in health-related quality-of-life measures. Ixekizumab is the company’s investigational medicine for the treatment of moderate-to-severe plaque psoriasis.
“These studies show ixekizumab – at two different dosing regimens – performed significantly better than etanercept or placebo, inducing a rapid and high level of psoriasis plaque resolution for patients with moderate-to-severe disease,” said Christopher Griffiths, M.D., FRCP, professor of dermatology at The University of Manchester, U.K. and primary study investigator. “Importantly, these clinical results were accompanied by noteworthy improvements to patient quality of life, and were achieved with a safety profile comparable to etanercept in these studies.”
In each study, co-primary efficacy objectives assessed whether ixekizumab administered once every two weeks or once every four weeks was superior to etanercept and placebo after twelve weeks, as measured by a Psoriasis Area and Severity Index reduction of at least 75 percent (PASI 75) and a Static Physician Global Assessment score of clear or minimal (sPGA 0/1).
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
During Morning trade, Shares of MetLife, Inc. (NYSE:MET), dipped -0.21%, and is now trading at $56.11.
MetLife Foundation released its 2014 Annual Report, Into Action, highlighting its activities and showcasing a broad array of partners, grantees and activities.
Over the last year, the Foundation has made noteworthy progress toward achieving its aims on financial inclusion. In 2013, the Foundation committed $200 million over five years to ensure that more people across the globe have access to the quality financial services they need to build better lives. To date, it has committed almost $70 million towards that aim. The report highlights the partners and areas where those grants have assisted advance the cause.
“This past year, as I have travelled around the globe meeting our non-profit partners and their clients, I have been amazed at the dedication they bring to the needs of the communities in which they operate. To see the difference that they are making in the lives of individuals and families is truly inspiring. My thanks to them for assisting us ensure that more people across the globe have access to quality financial services and products they need to build better lives,” said Dennis White, president and chief executive officer, MetLife Foundation.
In addition to financial inclusion, MetLife Foundation also supports other areas counting arts and culture, Alzheimer’s disease research and aging-related programs, youth education and community development. These projects bring noteworthy benefits to local communities around the world in which MetLife operates.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
